More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Regeneron’s Eylea Injection Prefilled Syringe Now Available
Author: Jennie Crabbe
Regeneron, of Tarrytown, New York, has announced that the Eylea (aflibercept) prefilled syringe is now available for doctors to order.
The 2 mg, single-dose, sterilized prefilled syringe requires fewer preparation steps compared with vials, the company said.
In the US, Eylea (aflibercept) is indicated to treat wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The vascular endothelial growth factor (VEGF) inhibitor is designed to block VEGF-A and placental growth factor.
Regeneron received FDA approval for the Eylea prefilled syringe in August.
Regeneron’s US net sales of Eylea in Q3-2019 totaled $1.19 billion, a 16 percent increase over Q3-2018.
